PubRank

Sunao Kaneko

Author PubWeight™ 125.88‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Digitalis intoxication induced by paroxetine co-administration. Lancet 2006 2.01
2 Mutations in EFHC1 cause juvenile myoclonic epilepsy. Nat Genet 2004 1.98
3 Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol 2010 1.81
4 Effect of dose timing in relation to food intake on systemic exposure to blonanserin. Eur J Clin Pharmacol 2010 1.47
5 Association between major Multidrug Resistance 1 (MDR1) gene polymorphisms and plasma concentration of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2007 1.38
6 Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in borderline SMEI (SMEB). Epilepsia 2004 1.24
7 Defective function of GABA-containing synaptic vesicles in mice lacking the AP-3B clathrin adaptor. J Cell Biol 2004 1.22
8 Genomewide high-density SNP linkage analysis of 236 Japanese families supports the existence of schizophrenia susceptibility loci on chromosomes 1p, 14q, and 20p. Am J Hum Genet 2005 1.11
9 Severe myoclonic epilepsy in infancy: clinical analysis and relation to SCN1A mutations in a Japanese cohort. Adv Neurol 2005 1.10
10 Mutational analysis of CACNA1G in idiopathic generalized epilepsy. Mutation in brief #962. Online. Hum Mutat 2007 1.03
11 Prevalence of metabolic syndrome among patients with schizophrenia in Japan. Schizophr Res 2010 1.02
12 Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol 2004 1.01
13 Genetics of idiopathic epilepsies. Epilepsia 2005 0.97
14 Staphylococcal enterotoxin induces emesis through increasing serotonin release in intestine and it is downregulated by cannabinoid receptor 1. Cell Microbiol 2007 0.97
15 Gender differences in factors associated with suicidal ideation and depressive symptoms among middle-aged workers in Japan. Ind Health 2012 0.94
16 The genetics of febrile seizures and related epilepsy syndromes. Brain Dev 2003 0.94
17 Microchromosomal deletions involving SCN1A and adjacent genes in severe myoclonic epilepsy in infancy. Epilepsia 2008 0.94
18 Patients with a sodium channel alpha 1 gene mutation show wide phenotypic variation. Epilepsy Res 2007 0.90
19 Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol 2011 0.90
20 The difference in Mismatch negativity between the acute and post-acute phase of schizophrenia. Biol Psychol 2002 0.89
21 Age-dependent modulation of hippocampal excitability by KCNQ-channels. Epilepsy Res 2003 0.89
22 Remapping and mutation analysis of benign adult familial myoclonic epilepsy in a Japanese pedigree. J Hum Genet 2011 0.88
23 Mortality in Dravet syndrome: search for risk factors in Japanese patients. Epilepsia 2011 0.88
24 Effects of ryanodine receptor activation on neurotransmitter release and neuronal cell death following kainic acid-induced status epilepticus. Epilepsy Res 2005 0.88
25 Different patterns of dipole source localization in gelastic seizure with or without a sense of mirth. Neurosci Res 2002 0.88
26 Retrospective multiinstitutional study of the prevalence of early death in Dravet syndrome. Epilepsia 2011 0.87
27 Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome. Am J Med Genet B Neuropsychiatr Genet 2003 0.87
28 Mutation (Ser284Leu) of neuronal nicotinic acetylcholine receptor alpha 4 subunit associated with frontal lobe epilepsy causes faster desensitization of the rat receptor expressed in oocytes. Epilepsy Res 2002 0.87
29 Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2009 0.87
30 No association between dietary patterns and depressive symptoms among a community-dwelling population in Japan. Ann Gen Psychiatry 2012 0.86
31 Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2008 0.86
32 Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders. Hum Psychopharmacol 2011 0.86
33 Prevalence of SCN1A mutations in children with suspected Dravet syndrome and intractable childhood epilepsy. Epilepsy Res 2012 0.86
34 No association between bone mass and prolactin levels among patients with schizophrenia. Hum Psychopharmacol 2011 0.86
35 Comparison of ankle-brachial pressure index and pulse wave velocity as markers of cognitive function in a community-dwelling population. BMC Psychiatry 2010 0.85
36 Effects of interleukin-1beta on hippocampal glutamate and GABA releases associated with Ca2+-induced Ca2+ releasing systems. Epilepsy Res 2006 0.85
37 Effect of age and disease on bone mass in Japanese patients with schizophrenia. Ann Gen Psychiatry 2012 0.85
38 A de novo KCNQ2 mutation detected in non-familial benign neonatal convulsions. Brain Dev 2008 0.85
39 Genetic abnormalities underlying familial epilepsy syndromes. Brain Dev 2002 0.85
40 Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia. J Clin Pharmacol 2003 0.85
41 Sex-specific effects of subjective memory complaints with respect to cognitive impairment or depressive symptoms. Psychiatry Clin Neurosci 2014 0.84
42 Comparison of prevalence of metabolic syndrome in hospital and community-based Japanese patients with schizophrenia. Ann Gen Psychiatry 2011 0.84
43 Relationship between plasma concentrations of trazodone and its active metabolite, m-chlorophenylpiperazine, and its clinical effect in depressed patients. Ther Drug Monit 2002 0.84
44 Association between plasma paroxetine concentration and changes in plasma brain‐derived neurotrophic factor levels in patients with major depressive disorder. Hum Psychopharmacol 2011 0.83
45 Dietary patterns are associated with obesity in Japanese patients with schizophrenia. BMC Psychiatry 2014 0.83
46 Zonisamide at clinically relevant concentrations inhibits field EPSP but not presynaptic fiber volley in rat frontal cortex. Epilepsy Res 2005 0.83
47 Protein kinase associated with gating and closing transmission mechanisms in temporoammonic pathway. Neuropharmacology 2004 0.82
48 Characteristics of the tree-drawing test in chronic schizophrenia. Psychiatry Clin Neurosci 2010 0.82
49 Body mass index and quality of life among outpatients with schizophrenia in Japan. BMC Psychiatry 2013 0.82
50 Depression increases the length of hospitalization for patients undergoing thoracic surgery: a preliminary study. Psychosomatics 2011 0.82
51 Hearing impairment and cognitive function among a community-dwelling population in Japan. Ann Gen Psychiatry 2011 0.82
52 Cytochrome P450 2C19 genetic polymorphisms in Ugandans. Eur J Clin Pharmacol 2008 0.82
53 Ankle brachial pressure index as a marker of apathy in a community-dwelling population. Int J Geriatr Psychiatry 2011 0.82
54 Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia 2004 0.81
55 Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors. Epilepsy Res 2005 0.81
56 Lack of potassium current in W309R mutant KCNQ3 channel causing benign familial neonatal convulsions (BFNC). Epilepsy Res 2009 0.81
57 Body composition in patients with schizophrenia: Comparison with healthy controls. Ann Gen Psychiatry 2012 0.81
58 Glucose metabolism in Japanese schizophrenia patients treated with risperidone or olanzapine. J Clin Psychiatry 2009 0.81
59 Minor genetic variants of the dopamine D4 receptor (DRD4) polymorphism are associated with novelty seeking in healthy Japanese subjects. Prog Neuropsychopharmacol Biol Psychiatry 2009 0.81
60 Mutational analysis of GABRG2 in a Japanese cohort with childhood epilepsies. J Hum Genet 2010 0.81
61 Differential effects of the hiba odor on CNV and MMN. Biol Psychol 2002 0.80
62 Spectrotemporal window of integration of auditory information in the human brain. Brain Res Cogn Brain Res 2003 0.80
63 Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects. Eur J Clin Pharmacol 2006 0.80
64 Possible associations between antioxidant enzyme polymorphisms and metabolic abnormalities in patients with schizophrenia. Neuropsychiatr Dis Treat 2013 0.80
65 Genetic analysis of PRRT2 for benign infantile epilepsy, infantile convulsions with choreoathetosis syndrome, and benign convulsions with mild gastroenteritis. Brain Dev 2012 0.80
66 Different serum concentrations of steady-state valproic acid in two sustained-release formulations. Psychiatry Clin Neurosci 2007 0.80
67 Impairment in activation of a frontal attention-switch mechanism in schizophrenic patients. Biol Psychol 2003 0.80
68 Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients. J Clin Psychopharmacol 2005 0.80
69 Rats harboring S284L Chrna4 mutation show attenuation of synaptic and extrasynaptic GABAergic transmission and exhibit the nocturnal frontal lobe epilepsy phenotype. J Neurosci 2008 0.80
70 Relationships between suicidal ideation and the dimensions of depressive symptoms among middle-aged population in Japan. J Affect Disord 2011 0.80
71 Involvement of Ca(2+)-induced Ca2+ releasing system in interleukin-1beta-associated adenosine release. Eur J Pharmacol 2006 0.80
72 Effects of CYP2C19 and P450 oxidoreductase polymorphisms on the population pharmacokinetics of clobazam and N-desmethylclobazam in japanese patients with epilepsy. Ther Drug Monit 2014 0.80
73 Steady-state pharmacokinetics of a new antipsychotic agent perospirone and its active metabolite, and its relationship with prolactin response. Ther Drug Monit 2004 0.79
74 Hyperpolarization-activated cyclic nucleotide gated channels: a potential molecular link between epileptic seizures and Aβ generation in Alzheimer's disease. Mol Neurodegener 2012 0.79
75 Therapeutic effects of bromperidol on the five dimensions of schizophrenic symptoms. Prog Neuropsychopharmacol Biol Psychiatry 2002 0.79
76 Time may be compressed in sound representation as replicated in sensory memory. Neuroreport 2005 0.79
77 Assessment of the Center for Epidemiological Studies Depression Scale factor structure among middle-aged workers in Japan. Psychiatry Clin Neurosci 2011 0.79
78 The influence of personality factors on paroxetine response time in patients with major depression. J Affect Disord 2011 0.79
79 Association between monoamine oxidase A (MAOA) and personality traits in Japanese individuals. Prog Neuropsychopharmacol Biol Psychiatry 2008 0.79
80 The efficacy of low-dose aripiprazole treatment for trichotillomania. Clin Neuropharmacol 2011 0.79
81 Personality types and coping style in hemodialysis patients. Psychiatry Clin Neurosci 2007 0.79
82 Hallucination induced by paroxetine discontinuation in patients with major depressive disorders. Psychiatry Clin Neurosci 2011 0.79
83 Is breast-feeding of infants advisable for epileptic mothers taking antiepileptic drugs? Psychiatry Clin Neurosci 2010 0.78
84 Differential effects of the catechol-O-methyltransferase Val158Met genotype on the cognitive function of schizophrenia patients and healthy Japanese individuals. PLoS One 2013 0.78
85 Treatment of partial seizures with gabapentin: double-blind, placebo-controlled, parallel-group study. Psychiatry Clin Neurosci 2006 0.78
86 Pharmacological discrimination of protein kinase associated exocytosis mechanisms between dopamine and 3,4-dihydroxyphenylalanine in rat striatum using in vivo microdialysis. Neurosci Lett 2004 0.78
87 Sound perception affected by nonlinear variation of accuracy in memory trace. Neuroreport 2004 0.78
88 Pregnane X receptor and hepatocyte nuclear factor 4α polymorphisms are cooperatively associated with carbamazepine autoinduction. Pharmacogenet Genomics 2014 0.78
89 Association between cytochrome P450 (CYP) 2C19 polymorphisms and harm avoidance in Japanese. Am J Med Genet B Neuropsychiatr Genet 2007 0.78
90 Comparing the influence of dopamine D₂ polymorphisms and plasma drug concentrations on the clinical response to risperidone. J Clin Psychopharmacol 2011 0.78
91 Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006 0.78
92 Comparing the influences of age and disease on distortion in the clock drawing test in Japanese patients with schizophrenia. Am J Geriatr Psychiatry 2010 0.78
93 DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study. J Clin Psychopharmacol 2012 0.78
94 Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes. Br J Clin Pharmacol 2004 0.78
95 Clock drawing performance in a community-dwelling population: Normative data for Japanese subjects. Aging Ment Health 2010 0.78
96 Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl) 2002 0.78
97 Properties of a novel GABAA receptor γ2 subunit mutation associated with seizures. J Pharmacol Sci 2012 0.78
98 Both 3,4-dihydroxyphenylalanine and dopamine releases are regulated by Ca2+-induced Ca2+ releasing system in rat striatum. Neurosci Lett 2004 0.78
99 Coping behaviors in relation to depressive symptoms and suicidal ideation among middle-aged workers in Japan. J Affect Disord 2012 0.78
100 Marital status of patients with epilepsy with special reference to the influence of epileptic seizures on the patient's married life. Epilepsia 2004 0.78
101 New-onset diabetic ketoacidosis in a schizophrenic patient with multiple autoimmune disease during treatment with risperidone. Prog Neuropsychopharmacol Biol Psychiatry 2007 0.77
102 Visual hallucinations during duloxetine treatment in a patient with major depressive disorder. Clin Neuropharmacol 2013 0.77
103 No association between hormonal abnormality and sexual dysfunction in Japanese schizophrenia patients treated with antipsychotics. Hum Psychopharmacol 2012 0.77
104 Hyperactivity of endoplasmic reticulum associated exocytosis mechanism contributes to acute phencyclidine intoxication. J Pharmacol Sci 2004 0.77
105 No association between CYP2D6 polymorphisms and personality trait in Japanese. Br J Clin Pharmacol 2007 0.77
106 Mutation screening of AP3M2 in Japanese epilepsy patients. Brain Dev 2007 0.77
107 Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 2003 0.77
108 Dysfunction of extrasynaptic GABAergic transmission in phospholipase C-related, but catalytically inactive protein 1 knockout mice is associated with an epilepsy phenotype. J Pharmacol Exp Ther 2011 0.77
109 Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders. Ther Drug Monit 2014 0.77
110 Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. Ther Drug Monit 2007 0.77
111 The development of memory trace depending on the number of the standard stimuli. Clin EEG Neurosci 2006 0.77
112 KCNQ2 abnormality in BECTS: benign childhood epilepsy with centrotemporal spikes following benign neonatal seizures resulting from a mutation of KCNQ2. Epilepsy Res 2012 0.77
113 Interaction between carbamazepine, zonisamide and voltage-sensitive Ca2+ channel on acetylcholine release in rat frontal cortex. Epilepsy Res 2002 0.77
114 Exocytosis mechanism as a new targeting site for mechanisms of action of antiepileptic drugs. Life Sci 2002 0.77
115 Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases. Epilepsy Res 2011 0.77
116 Identification of predictors of post-ictal delirium after electroconvulsive therapy. Psychiatry Clin Neurosci 2009 0.77
117 Association between plasma brain-derived neurotrophic factor levels and personality traits in healthy Japanese subjects. Psychiatry Res 2013 0.77
118 Association between the dopamine D2 receptor (DRD2) polymorphism and the personality traits of healthy Japanese participants. Prog Neuropsychopharmacol Biol Psychiatry 2012 0.77
119 Augmentation of antidepressants with perospirone for treatment-resistant major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 2009 0.77
120 Different effects of the selective serotonin reuptake inhibitors fluvoxamine, paroxetine, and sertraline on the pharmacokinetics of fexofenadine in healthy volunteers. J Clin Psychopharmacol 2012 0.77
121 Thioridazine inhibits risperidone metabolism: a clinically relevant drug interaction. J Clin Psychopharmacol 2005 0.77
122 Comparison of prolactin concentrations between haloperidol and risperidone treatments in the same female patients with schizophrenia. Psychopharmacology (Berl) 2002 0.77
123 The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 2004 0.76
124 Effective electroconvulsive therapy in a 92-year-old dementia patient with psychotic feature. Psychiatry Clin Neurosci 2007 0.76
125 Factor structure of the Liebowitz Social Anxiety Scale in community-dwelling subjects in Japan. Psychiatry Clin Neurosci 2012 0.76
126 Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. Ther Drug Monit 2009 0.76
127 [Mechanisms of interaction between adenosine receptor subtypes on hippocampal serotonin release]. Nihon Shinkei Seishin Yakurigaku Zasshi 2002 0.76
128 The effect of smoking status on the plasma concentration of prolactin already elevated by risperidone treatment in schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2011 0.76
129 A novel prophylactic effect of furosemide treatment on autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). Epilepsy Res 2013 0.76
130 Co-localization of beta-peptide and phosphorylated tau in astrocytes in a patient with corticobasal degeneration. Neuropathology 2006 0.76
131 Cognitive function among hemodialysis patients in Japan. Ann Gen Psychiatry 2011 0.76
132 Positive association between benign familial infantile convulsions and LGI4. Brain Dev 2009 0.76
133 Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol. Ther Drug Monit 2003 0.76
134 Determination of genomic breakpoints in an epileptic patient using genotyping array. Biochem Biophys Res Commun 2006 0.76
135 Determination of exocytosis mechanisms of DOPA in rat striatum using in vivo microdialysis. Neurosci Lett 2004 0.76
136 Effect of dietary fat content in meals on pharmacokinetics of quazepam. J Clin Pharmacol 2002 0.76
137 Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatment-resistance to dopamine antagonists in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2003 0.76
138 Hallucinations associated with modafinil treatment for narcolepsy. J Clin Psychopharmacol 2009 0.76
139 Memory trace dependence on number of stimuli in magnetic mismatch negativity. Neuroreport 2008 0.76
140 Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. J Clin Pharmacol 2002 0.76
141 Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve. Ther Drug Monit 2006 0.75
142 Impaired M-current and neuronal excitability. Epilepsia 2002 0.75
143 Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam. Br J Clin Pharmacol 2003 0.75
144 The CLOCK C3111T polymorphism is associated with reward dependence in healthy Japanese subjects. Neuropsychobiology 2012 0.75
145 Positional candidate approach for the gene responsible for benign adult familial myoclonic epilepsy. Epilepsia 2002 0.75
146 The characteristics of side-effects of bromperidol in schizophrenic patients. Psychiatry Clin Neurosci 2002 0.75
147 Comparative in vivo bioequivalence and in vitro dissolution of two valproic acid sustained-release formulations. Drug Des Devel Ther 2009 0.75
148 Fluvoxamine dose-dependent interaction with haloperidol and the effects on negative symptoms in schizophrenia. Psychopharmacology (Berl) 2003 0.75
149 Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding. Am J Med Genet 2002 0.75
150 Prolactin fluctuation over the course of a day during treatments with three atypical antipsychotics in schizophrenic patients. Hum Psychopharmacol 2010 0.75
151 Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010 0.75
152 Carbamazepine prevents breakdown of neurotransmitter release induced by hyperactivation of ryanodine receptor. Neuropharmacology 2007 0.75
153 Effects of valproate on neurotransmission associated with ryanodine receptors. Neurosci Res 2010 0.75
154 Comparison of prolactin concentrations between haloperidol and bromperidol treatments in schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2002 0.75
155 Poor reliability of therapeutic drug monitoring data for haloperidol and bromperidol using enzyme immunoassay. Ther Drug Monit 2003 0.75
156 [Expressive language disorder]. Ryoikibetsu Shokogun Shirizu 2003 0.75
157 [Clinical pharmacogenetics in the treatment of schizophrenia]. Nihon Shinkei Seishin Yakurigaku Zasshi 2005 0.75
158 Determination of fluvoxamine and its metabolite fluvoxamino acid by liquid-liquid extraction and column-switching high-performance liquid chromatography. J Pharm Biomed Anal 2005 0.75
159 Anger is a distinctive feature of epilepsy patients with depression. Tohoku J Exp Med 2014 0.75
160 Molecular genetics of human familial epilepsy syndromes. Epilepsia 2002 0.75
161 Attentional distraction of CNV depending on the spatial focus. Clin EEG Neurosci 2004 0.75
162 No association between polymorphism in tyrosine hydroxylase and personality traits in healthy Japanese subjects. Psychiatry Clin Neurosci 2010 0.75
163 Items of the Montgomery-Åsberg Depression Rating Scale Associated With Response to Paroxetine Treatment in Patients With Major Depressive Disorder. Clin Neuropharmacol 2016 0.75
164 Transient gamma-band response is dissociated from sensory memory as reflected by MMN. Neurosci Lett 2005 0.75
165 Prolonged depersonalization/derealization-like symptom after migraine headache: a case report. Neurol Sci 2014 0.75
166 Altered pharmacokinetics and metabolism of valproate after replacement of conventional valproate with the slow-release formulation in epileptic patients. Pharmacol Toxicol 2002 0.75
167 Improvement of tardive dyskinesia following zopiclone treatment. Prog Neuropsychopharmacol Biol Psychiatry 2009 0.75
168 [Epilepsy and personality]. Ryoikibetsu Shokogun Shirizu 2002 0.75
169 Bemegride lengthens seizure duration during electric convulsive therapy in a schizophrenic patient with increased seizure threshold. J ECT 2009 0.75
170 [Psychophysiological basis of smells]. Seishin Shinkeigaku Zasshi 2005 0.75
171 The association between sunshine duration and paroxetine response time in patients with major depressive disorder. J Affect Disord 2011 0.75
172 Early contingent negative variation (CNV) shows a small symmetrical negativity in a somatosensory paradigm. Clin Electroencephalogr 2002 0.75
173 Effects of age on paroxetine efficacy in patients with major depressive disorder who do not exhibit an early response to treatment. Clin Neuropharmacol 2015 0.75
174 Relationships between vascular endothelial growth factor levels and temperament and character inventory traits in healthy Japanese subjects. Neuropsychobiology 2013 0.75
175 Associations between side effects of nemonapride and plasma concentrations of the drug and prolactin. Prog Neuropsychopharmacol Biol Psychiatry 2002 0.75
176 A crossover study on the glucose metabolism between treatment with olanzapine and risperidone in schizophrenic patients. Exp Clin Psychopharmacol 2010 0.75
177 A case of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) coexisting with pervasive developmental disorder harboring SCN1A mutation in addition to CHRNB2 mutation. Epilepsy Behav 2012 0.75
178 [Genetic diagnosis for epilepsy]. Nihon Rinsho 2014 0.75
179 Paroxetine-associated hypereosinophilia may clinically resemble a panic attack. Clin Neuropharmacol 2012 0.75
180 Establishment of new cloned enzyme donor immunoassays (CEDIA) for haloperidol and bromperidol. Ther Drug Monit 2004 0.75
181 [Personalized medicine for epilepsy based on the pharmacogenomic testing]. Brain Nerve 2011 0.75
182 Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. J Clin Psychopharmacol 2003 0.75
183 On the likelihood of SCN1A microdeletions or duplications in Dravet syndrome with missense mutation. Brain Dev 2011 0.75
184 [Methodological consideration in studying the exocytosis mechanisms using microdialysis]. Nihon Shinkei Seishin Yakurigaku Zasshi 2004 0.75